OWCP Pengajuan SEC - OWC Pharmaceutical Research Corp.- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

1431934

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to OWC Pharmaceutical Research Corp.

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 25, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2021 OWC Pharmaceutical Research Corp. (Exact name of registrant as specified in its charter) Delaware 0-54856 98-0573566 (State or Other Jurisdiction (Commission (I.R.S. E
June 21, 2021	SC 13D/A	OWCP / OWC Pharmaceutical Research Corp / Discover Growth Fund, LLC - AMENDMENT NO. 2 TO SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2) OWC Pharmaceutical Research Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 26784V108 (CUSIP Number) Discover Growth Fund, LLC 5330 Yacht Haven Grande, Suite 206 St. Thomas, VI 00802 Attn: John Kirkland (340) 774-8800 (Name, Address a
June 21, 2021	SC 13G	OWCP / OWC Pharmaceutical Research Corp / Discover Growth Fund, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) OWC Pharmaceutical Research Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 26784V108 (CUSIP Number) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ? Rule 13d-1(b) ? Rule 13d-1(c) ? Rule 13d-1(d
March 30, 2021	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) OWC Pharmaceutical Research Corp. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP N UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) OWC Pharmaceutical Research Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 26784V108 (CUSIP Number) Discover Growth Fund, LLC 5330 Yacht Haven Grande, Suite 206 St. Thomas, VI 00802 Attn: John Kirkland (340) 774-8800 (Name, Address a
March 5, 2021	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2021 OWC Pharmaceutical Research Corp. (Exact name of registrant as specified in its charter) Delaware 0-54856 98-0573566 (State or Other Jurisdiction (Commission (I.R.S.
March 5, 2021	SC 13D/A	OWCP / OWC Pharmaceutical Research Corp. / Discover Growth Fund - AMENDMENT NO.1 TO FORM SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) OWC Pharmaceutical Research Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 26784V108 (CUSIP Number) Discover Growth Fund, LLC 5330 Yacht Haven Grande, Suite 206 St. Thomas, VI 00802 Attn: John Kirkland (340) 774-8800 (Name, Address a
February 25, 2021	SC 13D	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 OWC Pharmaceutical Research Corp. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) Discover Grow UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 OWC Pharmaceutical Research Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 26784V108 (CUSIP Number) Discover Growth Fund, LLC 5330 Yacht Haven Grande, Suite 206 St. Thomas, VI 00802 Attn: John Kirkland (340) 774-8800 (Name, Address and Telephone Number
December 14, 2020	8-K	Other Events - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2020 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
November 3, 2020	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (
September 25, 2020	8-K	Submission of Matters to a Vote of Security Holders - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2020 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (
September 16, 2020	8-K	Submission of Matters to a Vote of Security Holders - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2020 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (
September 4, 2020	DEFA14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [ ] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy
September 2, 2020	8-K	Submission of Matters to a Vote of Security Holders - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2020 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R
August 14, 2020	DEF 14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [ ] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ X ] Definitive
July 27, 2020	PRER14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [ ] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)
July 22, 2020	PRE 14A	- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [ ] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P
June 26, 2020	15-12G/A	- OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0167 Expires: November 30, 2010 Estimated average burden hours per response . . . . . . . . . . 1.50 FORM 15/A CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE
June 26, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2020 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
June 24, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2020 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
March 31, 2020	15-12G	OWCP / OWC Pharmaceutical Research Corp. 15-12G - - OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0167 Expires: November 30, 2010 Estimated average burden hours per response . . . . . . . . . . 1.50 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE S
March 31, 2020	8-K	Other Events, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): March 30, 2020 OWC Pharmaceutical Research Corp. (Exact Name of Issuer as Specified in Charter) Delaware 000-54856 98-0573566 (State or Other Jurisdiction of Incorpo
March 31, 2020	EX-99.1	OWC PHARMACEUTICAL RESEARCH ANNOUNCES INTENTION TO DEREGISTER ITS COMMON STOCK EX-99.1 2 ex99-1.htm EXHIBIT 99.1 NEWS FOR IMMEDIATE RELEASE Contact: Zvi Riterband, CEO Investor Relations OWC Pharmaceutical Research Corp. Phone: +972-72-260-8004 Email: [email protected] OWC PHARMACEUTICAL RESEARCH ANNOUNCES INTENTION TO DEREGISTER ITS COMMON STOCK RAMAT GAN, ISRAEL: March 31, 2020 — OWC Pharmaceutical Research Corp. (OTC QB: OWCP), an early stage medical cannabis research an
March 27, 2020	8-K	Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 19, 2020 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.
March 18, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2020 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.
March 9, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2020 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
February 26, 2020	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 13, 2019 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
December 26, 2019	8-K	Financial Statements and Exhibits, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2019 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of
December 26, 2019	EX-3.1	Certificate of Designation of Series B Convertible Preferred Stock of OWC Pharmaceutical Research Corp. CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES B CONVERTIBLE PREFERRED STOCK OF OWC PHARMACEUTICAL RESEARCH CORP.
December 12, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 12, 2019 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
November 26, 2019	DEFA14A	OWCP / OWC Pharmaceutical Research Corp. DEFA14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, For Use of the Commission Only (as permitted by Rule
November 20, 2019	424B3	OWC Pharmaceutical Research Corp. 269,739,284 Shares of Common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-231865 Prospectus Supplement No. 2 OWC Pharmaceutical Research Corp. 269,739,284 Shares of Common stock This prospectus supplement no. 2 relates to the offer and sale from time to time of up to 269,739,284 shares of our common stock by the selling stockholder listed on page 74 of this prospectus. The number of shares offered for sale by the sel
November 19, 2019	DEF 14A	OWCP / OWC Pharmaceutical Research Corp. DEF 14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]
November 13, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2019 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
November 13, 2019	10-Q	Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54856 OWC PHARMACEU
November 8, 2019	PRE 14A	OWCP / OWC Pharmaceutical Research Corp. PRE 14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ]
October 28, 2019	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 22, 2019 Owc Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
October 7, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2019 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R
September 18, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2019 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (
September 10, 2019	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 29, 2019 Owc Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R
August 22, 2019	424B3	OWC Pharmaceutical Research Corp. 269,739,284 Shares of Common stock 424B3 1 form424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-231865 Prospectus Supplement No. 1 OWC Pharmaceutical Research Corp. 269,739,284 Shares of Common stock This prospectus supplement no. 1 relates to the offer and sale from time to time of up to 269,739,284 shares of our common stock by the selling stockholder listed on page 74 of this prospectus. The number of shares offer
August 13, 2019	10-Q	OWCP / OWC Pharmaceutical Research Corp. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54856 OWC PHARMACEUTICAL
August 7, 2019	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 23, 2019 Owc Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S.
July 24, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2019 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
July 8, 2019	424B3	OWC Pharmaceutical Research Corp. 269,739,284 Shares of Common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-231865 Prospectus OWC Pharmaceutical Research Corp. 269,739,284 Shares of Common stock This prospectus relates to the offer and sale from time to time of up to 269,739,284 shares of our common stock by the selling stockholder listed on page 74 of this prospectus. The number of shares offered for sale by the selling stockholder consists of up to
June 27, 2019	CORRESP	OWCP / OWC Pharmaceutical Research Corp. CORRESP - - OWC PHARMACEUTICAL RESEARCH CORP. 2 Ben Gurion St., Ramat Gan Israel 5257334 June 27, 2019 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Caleb French Re: OWC Pharmaceutical Research Corp. Registration Statement on Form S-1 Filed May 31, 2019 File No. 333-231865 Request for Acceleration Ladies and Gentleman: Pursuan
May 31, 2019	S-1	OWCP / OWC Pharmaceutical Research Corp. S-1 - Registration Statement - As filed with the Securities and Exchange Commission on May 31, 2019 Registration No.
May 21, 2019	424B3	OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock 424B3 1 form424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-225641 Prospectus Supplement No. 7 OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock This prospectus supplement no. 7 (the “Prospectus Supplement”) supplements the information contained in the prospectus dated July 3, 2018 (the “Prospectus”) relating to the offer and sale from time to time of up to 47,500
May 15, 2019	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54856 OWC PHARMACEUTICA
May 7, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S.
April 30, 2019	EX-10.29	Service agreement by and between the Company and Dr. Oron Yacoby Zeevi, dated October 1, 2018 EX-10.29 6 ex10-29.htm One World Cannabis Ltd. Consulting Agreement This Agreement (“Agreement”) is entered into as of October 1, 2018 (the “Effective Date”), by and between One World Cannabis Ltd., an Israeli company with offices at 30 Shaham St., Petach-Tikva, Israel (the “Company”) and Kinarti Ltd., an Israeli Company No. 515530731 with its principal place of business at 204 Hanarkissim St., Bi
April 30, 2019	EX-10.26	Amendment to executive employment agreement by and between the Company and Yossi Dagan, dated April 10, 2018 April 10, 2018 To: Yossi Dagan Re: Change to Scope of Employment Dear Yossi, Reference is made herein to the Personal Employment Agreement between you and One World Cannabis Ltd.
April 30, 2019	EX-14.1	Code of Business Conduct and Ethics, dated April 15, 2019. EX-14.1 7 ex14-1.htm OWC PHARMACEUTICAL RESEARCH CORP. CODE OF BUSINESS CONDUCT AND ETHICS Adopted as of April 2019 This Code of Business Conduct and Ethics (this “Code”) covers a wide range of business practices and procedures. It does not cover every issue that may arise, but it sets out basic principles to guide all employees of OWC Pharmaceutical Research Corp. and its subsidiaries and affilia
April 30, 2019	10-K/A	OWCP / OWC Pharmaceutical Research Corp. 10-K/A Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001
April 30, 2019	EX-10.28	Amendment to service agreement between Mr. Bignitz and the Company, dated May 21, 2018 EX-10.28 5 ex10-28.htm 21.5.2018 To: MB&B Business Creation Ltd. Re: Amendment to Consulting Agreement Dear Sirs, Reference is made to the Consulting Agreement between you and One World Cannabis Ltd. (the “Company”), dated August 1, 2017 as amended (the “Agreement”; capitalized terms not defined herein shall have the meaning given to them in the Agreement). This letter hereby documents the agreeme
April 30, 2019	EX-10.27	Amendment to executive employment agreement by and between the Company and Yossi Dagan, dated July 1, 2018 July 1, 2018 To: Yossi Dagan Re: Amendment to Employment Agreement Dear Yossi, Reference is made to your employment agreement with One World Cannabis Ltd.
April 30, 2019	EX-10.25	Amendment to executive employment agreement by and between the Company and Alon Sinai, dated February 2, 2018 PERSONAL EMPLOYMENT AGREEMENT THIS PERSONAL EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of February 1, 2018 by and between One World Cannabis Ltd.
April 29, 2019	424B3	OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-225641 Prospectus Supplement No. 6 OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock This prospectus supplement no. 6 (the “Prospectus Supplement”) supplements the information contained in the prospectus dated July 3, 2018 (the “Prospectus”) relating to the offer and sale from time to time of up to 47,500,000 shares of our com
April 22, 2019	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 22, 2019 Owc Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
April 15, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 15, 2019 Owc Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.
April 8, 2019	424B3	OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock 424B3 1 form424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-225641 Prospectus Supplement No. 5 OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock This prospectus supplement no. 5 (the “Prospectus Supplement”) supplements the information contained in the prospectus dated July 3, 2018 (the “Prospectus”) relating to the offer and sale from time to time of up to 47,500
April 5, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 4, 2019 Owc Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
April 1, 2019	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-54856 OWC Pharmac
April 1, 2019	EX-3.1	Articles of Incorporation, as amended. EX-3.1 2 ex3-1.htm State of Delaware Secretary of State Division of Corporations Delivered 10:26 AM 03/06/2008 FILED 10:21 AM 03/06/2008 SRV 080288821 - 4514760 FILE STATE OF DELAWARE CERTIFICATE OF INCORPORATION OF DYNAMIC APPLICATIONS CORP. FIRST: The name of this Corporation is Dynamic Applications Corp. SECOND: Its registered office in the State of Delaware is to be located at 113 Barksdale Pr
March 14, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2019 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.
March 13, 2019	S-8	OWCP / OWC Pharmaceutical Research Corp. S-8 1 forms-8.htm Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OWC Pharmaceutical Research Corp. (Exact name of registrant as specified in its charter) Delaware 98-0573566 (State of Incorporation) (I.R.S. Employer Identification No.) 2 Ben Gurion Street Ramat Gan, Israel 4514760 (212)
March 13, 2019	EX-4.1	Amended and Restated 2016 Employees Share Option Plan (Incorporated by reference to Exhibit 4.1 to the Company’s Form S-8 filed on March 13, 2019). OWC PHARMACEUTICAL RESEARCH CORP. AMENDED AND RESTATED 2016 ISRAELI EMPLOYEE SHARE OPTION PLAN Effective February 5, 2019 1 PREFACE This plan, as amended from time to time, shall be known as the “OWC Pharmaceutical Research Corp.” -Israeli Employee Share Option Plan” (the “Plan”). 1. PURPOSE OF THE PLAN The purpose of this Plan is to foster and promote the long-term financial success of OWC and it
February 26, 2019	DEF 14A	OWCP / OWC Pharmaceutical Research Corp. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]
February 14, 2019	424B3	OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-225641 Prospectus Supplement No. 4 OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock This prospectus supplement no. 4 (the “Prospectus Supplement”) supplements the information contained in the prospectus dated July 3, 2018 (the “Prospectus”) relating to the offer and sale from time to time of up to 47,500,000 shares of our com
February 11, 2019	8-K/A	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 5, 2019 Owc Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of
February 8, 2019	PRE 14A	OWCP / OWC Pharmaceutical Research Corp. PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [X] Preliminary Proxy Statement [ ]
February 7, 2019	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 5, 2019 Owc Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
February 7, 2019	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 1, 2019 Owc Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of
February 4, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 1, 2019 Owc Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
January 29, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 29, 2019 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
December 31, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 31, 2018 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
December 11, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 30, 2018 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
December 4, 2018	424B3	OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-225641 Prospectus Supplement No. 3 OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock This prospectus supplement no. 3 (the “Prospectus Supplement”) supplements the information contained in the prospectus dated July 3, 2018 (the “Prospectus”) relating to the offer and sale from time to time of up to 47,500,000 shares of our com
November 30, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 30, 2018 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
November 28, 2018	424B3	OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-225641 Prospectus Supplement No. 2 OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock This prospectus supplement no. 2 (the “Prospectus Supplement”) supplements the information contained in the prospectus dated July 3, 2018 (the “Prospectus”) relating to the offer and sale from time to time of up to 47,500,000 shares of our com
November 8, 2018	10-Q	OWCP / OWC Pharmaceutical Research Corp. 10-Q (Quarterly Report) 10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000
October 22, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 22, 2018 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
August 21, 2018	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 21, 2018 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
August 21, 2018	EX-17.1	Letter of Resignation from Ms. Hannah Feuer to the Board of Directors of OWC Pharmaceutical Research Corp., dated August 20, 2018. EX-17.1 2 ex17-1.htm August 20, 2018 To the attention of: Mr. Mordechai Bignitz, CEO. OWC Pharmaceutical Research Corp. Mr. Yossi Dagan, CFO. OWC Pharmaceutical Research Corp. Moti and Yossi Shalom, Unfortunately, I would like to notify you that I will be resigning from the board and audit committee at OWC Pharmaceutical Research Corp. I would like to thank you and my colleagues on the board of di
August 21, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 21, 2018 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R
August 21, 2018	EX-17.1	Letter of Resignation from Ms. Hannah Feuer to the Board of Directors of OWC Pharmaceutical Research Corp., dated August 17, 2018 (incorporated by reference to Exhibit 17.1 to the Company’s Current Report on Form 8-K filed on August 21, 2018). EX-17.1 2 ex17-1.htm August 20, 2018 To the attention of: Mr. Mordechai Bignitz, CEO. OWC Pharmaceutical Research Corp. Mr. Yossi Dagan, CFO. OWC Pharmaceutical Research Corp. Moti and Yossi Shalom, Unfortunately, I would like to notify you that I will be resigning from the board and audit committee at OWC Pharmaceutical Research Corp. I would like to thank you and my colleagues on the board of di
August 17, 2018	424B3	OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-225641 Prospectus Supplement No. 1 OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock This prospectus supplement no. 1 (the “Prospectus Supplement”) supplements the information contained in the prospectus dated July 3, 2018 (the “Prospectus”) relating to the offer and sale from time to time of up to 47,500,000 shares of our com
August 16, 2018	10-Q	OWCP / OWC Pharmaceutical Research Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-54856 OWC PHARMACEUTICAL
August 14, 2018	NT 10-Q	OWCP / OWC Pharmaceutical Research Corp. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OWC Pharmaceutical Research Corp. (Full Name of Registrant) FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54856 (Check One): [ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: June 30, 2018 [ ] Transition Report on Form 10-K [ ] Transition Report
August 1, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): August 1, 2018 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.
July 3, 2018	424B3	OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-225641 Prospectus OWC Pharmaceutical Research Corp. 47,500,000 Shares of Common stock This prospectus relates to the offer and sale from time to time of up to 47,500,000 shares of our common stock by the selling stockholder listed on page 61 of this prospectus. The number of shares offered for sale by the selling stockholder consists of up to (
June 29, 2018	CORRESP	OWCP / OWC Pharmaceutical Research Corp. CORRESP OWC PHARMACEUTICAL RESEARCH CORP. 2 Ben Gurion St., Ramat Gan Israel 5257334 June 28, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Caleb French Re: OWC Pharmaceutical Research Corp. Registration Statement on Form S-1 Filed June 14, 2018, as amended on June 28, 2018 File No. 333-225641 Request for Acceleration
June 28, 2018	S-1/A	OWCP / OWC Pharmaceutical Research Corp. S-1/A As filed with the Securities and Exchange Commission on June 28 , 2018. Registration No. 333- 225641 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S- 1 /A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OWC Pharmaceutical Research Corp. (Exact name of registrant as specified in its charter) Delaware 3841 98-0573566 (State or other jurisdiction of incorporatio
June 28, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 28, 2018 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
June 28, 2018	CORRESP	OWCP / OWC Pharmaceutical Research Corp. CORRESP OWC PHARMACEUTICAL RESEARCH CORP. 2 Ben Gurion St., Ramat Gan Israel 5257334 June 28, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Caleb French Re: OWC Pharmaceutical Research Corp. Registration Statement on Form S-1 Filed June 14, 2018, as amended on June 28, 2018 File No. 333-225641 Request for Acceleration
June 14, 2018	S-1	Power of Attorney ( previously filed ). As filed with the Securities and Exchange Commission on June 14, 2018. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OWC Pharmaceutical Research Corp. (Exact name of registrant as specified in its charter) Delaware 3841 98-0573566 (State or other jurisdiction of incorporation or organiz
June 13, 2018	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 13, 2018 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
May 15, 2018	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-548
May 9, 2018	8-K/A	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2018 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of
May 3, 2018	EX-4.1	Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 3, 2018) EX-4.1 3 ex4-1.htm EXECUTION DRAFT NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “SECURITIES ACT”), AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UND
May 3, 2018	EX-4.2	Registration Rights Agreement dated April 30, 2018 (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on May 3, 2018) EX-4.2 4 ex4-2.htm EXECUTION DRAFT REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated April 30, 2018, by and between OWC Pharmaceutical Research Corp., a Delaware corporation (the “Company”), and the other parties who execute this Agreement (collectively, the “Purchasers”). Capitalized terms used herein and not otherwise defined herein shall have the respect
May 3, 2018	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2018 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of In
May 3, 2018	EX-3.1	Certificate of Designation of Series A Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on May 3, 2018). EX-3.1 2 ex3-1.htm CERTIFICATE OF DESIGNATIONS, PREFERENCES AND RIGHTS OF THE SERIES A CONVERTIBLE PREFERRED STOCK OF OWC PHARMACEUTICAL RESEARCH CORP. I, Mordechai Bignitz, hereby certify that I am the Chief Executive Officer of OWC Pharmaceutical Research Corp. (the “Corporation”), a corporation organized and existing under the Delaware General Corporation Law (the “DGCL”), and further do hereby
May 3, 2018	EX-10.1	Form of Securities Purchase Agreement dated April 30, 2018, by and between the Company and a non-US based institutional purchaser (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 3, 2018) SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated April 30, 2018 (the “Execution Date”), is by and among OWC Pharmaceutical Research Corp.
April 30, 2018	10-K/A	OWCP / OWC Pharmaceutical Research Corp. 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001
April 16, 2018	EX-3.1	Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K filed on April 16, 2018). EX-3.1 2 ex3-1.htm
April 16, 2018	EX-10.21	Executive Employment Agreement by and between the Company and Dr. Oron Yacoby Zeevi, dated February 18, 2018 (incorporated by reference to Exhibit 10.21 to the Company’s Annual Report on Form 10-K filed on April 16, 2018) Personal Employment Agreement This Personal Employment Agreement (“Agreement”) is entered into as of February 18, 2018, by and between One World Cannabis Ltd.
April 16, 2018	EX-10.24	2016 Employees Stock Option Plan (incorporated by reference to Exhibit 10.24 to the Company’s Annual Report on Form 10-K filed on April 16, 2018) EX-10.24 8 ex10-24.htm OWC PHARMACEUTICAL RESEARCH CORP. 2016 ISRAELI EMPLOYEE SHARE OPTION PLAN 1 PREFACE This plan, as amended from time to time, shall be known as the “OWC Pharmaceutical Research Corp.” -Israeli Employee Share Option Plan” (the “Plan”). 1. PURPOSE OF THE PLAN The purpose of this Plan is to foster and promote the long-term financial success of OWC and its Affiliates and increase
April 16, 2018	EX-21.1	Subsidiaries of the Company (incorporated by reference to Exhibit 21.1 to the Company’s Annual Report on Form 10-K filed on April 16, 2018). Exhibit 21.1 Subsidiaries Entity Jurisdiction of Organization One World Cannabis Ltd. Israel
April 16, 2018	EX-10.25	Employee’s Option Grant Form (incorporated by reference to Exhibit 10.25 to the Company’s Annual Report on Form 10-K filed on April 16, 2018) 102 Grant letter July 1, 2017 owc pharmaceutical research corp. The “Company” Grant Letter To the Optionee, , holder of Israeli identity card number , from , Israel. 1. You are hereby notified that on the Board of Directors of the Company (the “Board”) has resolved to grant you options, each to purchase one (1) Ordinary Share of the Company, nominal value of US$ 0.0001 each (the “Option” and/or “O
April 16, 2018	EX-10.22	Executive Consulting Agreement by and between the Company and Dr. Stanley Hirsch, dated July 24, 2017 (incorporated by reference to Exhibit 10.22 to the Company’s Annual Report on Form 10-K filed on April 16, 2018) Consulting Agreement This consulting agreement (the “Agreement”) is entered into as of July 24, 2017, by and between One World Cannabis Ltd, an Israeli company with its principal place of business at 30 Shaham St.
April 16, 2018	10-K	OWCP / OWC Pharmaceutical Research Corp. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-54856 OWC Pharmac
April 16, 2018	EX-10.23	Audit Committee Charter (incorporated by reference to Exhibit 10.23 to the Company’s Annual Report on Form 10-K filed on April 16, 2018). OWC PHARMACEUTICAL RESEARCH CORP. Audit Committee Charter Purpose The Committee is appointed by the Board of Directors of OWC Pharmaceutical Research Corp. (the “Company”) to (a) assist the Board in its oversight of (i) the integrity of the Company’s consolidated financial statements, (ii) the Company’s compliance with legal and regulatory requirements, (iii) the Company’s system of internal contr
April 16, 2018	EX-10.18	Executive Employment Agreement by and between the Company and Alon Sinai, dated February 1, 2018 (incorporated by reference to Exhibit 10.18 to the Company’s Annual Report on Form 10-K filed on April 16, 2018) PERSONAL EMPLOYMENT AGREEMENT THIS PERSONAL EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into as of February 1, 2018 by and between One World Cannabis Ltd.
April 16, 2018	EX-10.20	Executive Employment Agreement by and between the Company and Yossi Dagan, dated June 4, 2017 (incorporated by reference to Exhibit 10.20 to the Company’s Annual Report on Form 10-K filed on April 16, 2018) Personal Employment Agreement This Personal Employment Agreement (“Agreement”) is entered into as of June 4, 2017, by and between One World Cannabis Ltd.
April 2, 2018	NT 10-K	OWCP / OWC Pharmaceutical Research Corp. NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54856 (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR [ ] Form N-CSR For Period Ended: December 31, 2017 [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on Form 11-K [ ] Tra
March 8, 2018	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 8, 2018 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
March 8, 2018	EX-17.5	Letter of Resignation of Jeffrey Friedland dated March 5, 2018 (incorporated by reference to Exhibit 17.5 to the Company’s Current Report on Form 8-K filed on March 8, 2018) EXHIBIT 17.5 Letter of Resignation March 7, 2018 OWC Pharmaceutical Research Corp. Board of Directors Ladies and Gentlemen: I hereby submit my resignation as a member of the Advisory Board of OWC Pharmaceutical Research Corp., effective immediately. Respectfully, /s/: Jeffrey Friedland Jeffrey Friedland
March 5, 2018	EX-99.1	YouTube.com video interview of OWCP's Chairman, Dr. Stanley Hirsch, by CEOlive dated February 21, 2018, filed herewith. Exhibit 99.1 https://www.youtube.com/watch?v=VkW756ZSv0&feature=youtu.be
March 5, 2018	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 5, 2018 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
February 20, 2018	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 20, 2018 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
February 20, 2018	EX-99.1	OWC Pharmaceutical Research Corp. Appoints Dr. Oron Yacoby Zeevi as its Chief Scientific Officer EXHIBIT 99.1 OWC Pharmaceutical Research Corp. Appoints Dr. Oron Yacoby Zeevi as its Chief Scientific Officer Ramat Gan, Israel, February 20, 2018 /PRNewswire/ ? OWC Pharmaceutical Research Corp. (OTCQB: OWCP), (?OWC? or the ?Company?), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Oron Yacoby Ze
December 20, 2017	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 20, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
December 20, 2017	EX-99.1	OWC Pharmaceutical Research Corp. [OTCQB: OWCP] Announces Update on its Proprietary Medical Cannabis Sublingual Tablet EX-99.1 2 ex99-1.htm EXHIBIT 99.1 OWC Pharmaceutical Research Corp. [OTCQB: OWCP] Announces Update on its Proprietary Medical Cannabis Sublingual Tablet In December 2017, OWC Pharmaceutical Research Corp received a new permit from the Israel Medical Cannabis Agency [MCA] to proceed with the safety study of their oral disintegrating tablet. The study protocol will be submitted to the Institutional
November 15, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 31, 2017 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
November 14, 2017	10-Q	OWCP / OWC Pharmaceutical Research Corp. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 98-0573566 (State of Incorporation) (I.R.S. Emp
October 10, 2017	10-Q/A	OWCP / OWC Pharmaceutical Research Corp. 10-Q/A (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 98-0573566 (State or other Jurisdiction of Incorporation) (IRS
October 6, 2017	10-K/A	OWCP / OWC Pharmaceutical Research Corp. 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment #2 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 Commission file number 0-54856 OWC Pharmaceutical Research Corp. (Exact Name Of Registrant As Specified In Its Charter) Delaware 98-0573566 (State of Incorporation) (I.R.
September 13, 2017	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 13, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (
September 13, 2017	EX-99	September 14, 2017 Exhibit 99 Exhibit 99.1 September 14, 2017 Letter from the Chairman To our Shareholders, Following my recent appointment as Chairman at OWC Pharma (OTCQB: OWCP), it is my pleasure to introduce myself to you and to initiate a new tradition of biannual shareholder update letters. On the personal front, I am a biologist by training with a D. Phil. Degree from Oxford University in Cell Biology and Imm
September 12, 2017	8-K	Financial Statements and Exhibits, Other Events 8-K 1 owcp09122017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 12, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware
September 12, 2017	EX-99	Pfizer (PFE) and OWC Pharmaceutical (OWCP) Exhibit 99 Exhibit 99.1 Pfizer (PFE) and OWC Pharmaceutical (OWCP) Pfizer (PFE) to partner with OWC Pharmaceutical (OWCP) in new psoriasis and migraine cannabinoid-based therapy trials. Our source at Pfizer tells us that executives there strongly believe that Pfizer needs to increase it's cannabinoid pipeline to stay abreast of other big pharmaceutical companies who are now entering this sector. S
August 21, 2017	10-Q	OWCP / OWC Pharmaceutical Research Corp. 10-Q (Quarterly Report) 10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 98-0573566 (State or other Jurisdiction of In
August 14, 2017	NT 10-Q	OWC Pharmaceutical Research LATE NOTIFICATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OWC Pharmaceutical Research Corp. (Full Name of Registrant) FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54856 (Check One): [ ]Form 10-K [ ] Form 20-F [ ]Form 11-K [X] Form 10Q [ ] Form N-SAR [ ] For Period Ended: [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on For
August 1, 2017	8-K/A	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 26, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R
July 24, 2017	8-K	OWC Pharmaceutical Research (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 24, 2017 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
July 24, 2017	EX-99.1	OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its active chairman Dr. Hirsch has extensive scientific, executive and board level experience, directly related to OWCP’s current scientific and business development efforts. EXHIBIT 99.1 OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its active chairman Dr. Hirsch has extensive scientific, executive and board level experience, directly related to OWCP?s current scientific and business development efforts. PETACH TIKVA, Israel, July 25th, 2017 /PRNewswire/ - OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies tar
July 21, 2017	10-K/A	OWCP / OWC Pharmaceutical Research Corp. 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 Commission file number 0-54856 OWC Pharmaceutical Research Corp. (Exact Name Of Registrant As Specified In Its Charter) Delaware 98-0573566 (State of Incorporation) (I.R.S. Employer I
June 30, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): July 1, 2017 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S.
June 26, 2017	EX-99	PETACH TIKVA, Israel, June 27, 2017 - OWC Pharmaceutical Research Corp. (OTCQB: OWCP) today announced that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd (OWC), has filed a patent application with the United States Patent and Trade
June 26, 2017	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 26, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
June 14, 2017	EX-17	Letter of Resignation of Mr. Shmuel De-Saban dated June 12, 2017 (incorporated by reference to Exhibit 17.5 to the Company’s Current Report on Form 8-K filed on June 15, 2017). Exhibit 17.5 Shmuel De-Saban June 12, 2017 Board of Directors OWC Pharmaceutical Research Corp. 30 Shacham Street, P.O.B. 8324 Petach Tikva, 4918103 Israel Re: Letter of Resignation Gentlemen: I hereby resign as Chief Financial Officer of OWC Pharmaceutical Research Corp. (the "Registrant") and of its wholly-owned Israeli subsidiary, One World Cannabis Ltd, effective Monday, June 5, 2017. The reas
June 14, 2017	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 12, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
June 7, 2017	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): June 5, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S.
May 30, 2017	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 30, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S.
May 30, 2017	EX-99	OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts The Initial Objective of the Collaboration is the Introduction of OWC's Active Cannabinoid-Based Topical Psoriasis Cream to the German OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts The Initial Objective of the Collaboration is the Introduction of OWC's Active Cannabinoid-Based Topical Psoriasis Cream to the German Market PETACH TIKVA, Israel, May 31, 2017 - OWC Pharmaceutical Research Corp. (OTC: OWCP) and mediq Innovation Partners (mediq) are pleased to announc
May 18, 2017	10-Q	OWC Pharmaceutical Research FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 2017 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 Commission file number 0-54856 OWC Pharmaceutical Research Corp. (Exact Name of Registrant in its Charter) Delaware 98-0573566 (State or other Jurisdiction of Incorporation) (IRS Emp
May 15, 2017	NT 10-Q	OWC Pharmaceutical Research LATE NOTIFICATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OWC Pharmaceutical Research Corp. (Full Name of Registrant) FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54856 (Check One): [ ]Form 10-K [ ] Form 20-F [ ]Form 11-K [X] Form 10Q [ ] Form N-SAR [ ] For Period Ended: [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on For
May 5, 2017	8-K/A	Other Events 8-K/A 1 owcp8k05052017.htm AMENDED CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 6, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856
May 2, 2017	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 21, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.
May 2, 2017	EX-99	OWC Pharmaceutical Research Announces Update on Multiple Myeloma Study OWC Pharmaceutical Research Announces Update on Multiple Myeloma Study PETACH TIKVA, Israel, May 3, 2017 OWC Pharmaceutical Research Corp.
April 19, 2017	8-K	Other Events 8-K 1 owcp04192017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 12, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-
April 17, 2017	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 Commission file number 0-54856 OWC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 Commission file number 0-54856 OWC Pharmaceutical Research Corp. (Exact Name Of Registrant As Specified In Its Charter) Delaware 98-0573566 (State of Incorporation) (I.R.S. Employer Ide
April 4, 2017	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): April 4, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
April 4, 2017	EX-99	OWC Pharmaceutical Research Corp. Announces World-Wide Expression of Interest in its Cannabis-Based Topical Cream for Treatment of Psoriasis and other Skin Disorders Recent Clinical Tests Reflected up to 70% Improvement in Proliferation and Inflammat OWC Pharmaceutical Research Corp. Announces World-Wide Expression of Interest in its Cannabis-Based Topical Cream for Treatment of Psoriasis and other Skin Disorders Recent Clinical Tests Reflected up to 70% Improvement in Proliferation and Inflammation Markers Associated with Psoriasis PETACH TIKVA, Israel, April 5, 2017 /PRNewswire /OWC Pharmaceutical Research Corp. OTCQB: OWCP, ("OWC" or the "C
March 31, 2017	NT 10-K	OWC Pharmaceutical Research LATE NOTIFICATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OWC Pharmaceutical Research Corp. (Full Name of Registrant) FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54856 (Check One): [X]Form 10-K [ ] Form 20-F [ ]Form 11-K [ ] Form 10Q [ ] Form N-SAR [ ] For Period Ended: [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on For
March 20, 2017	8-K	Financial Statements and Exhibits, Other Events 8-K 1 owcp8k3202017.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 20, 2017 OWC Pharmaceutical Research Corp. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98
March 20, 2017	EX-99	OWC Pharmaceutical Research Corp Releases Promising Preliminary Results from Efficacy Tests of its Topical Cream The Company expects that its Topical Cream will be Market-Ready in Q2 2017 OWC Pharmaceutical Research Corp Releases Promising Preliminary Results from Efficacy Tests of its Topical Cream The Company expects that its Topical Cream will be Market-Ready in Q2 2017 PETACH TIKVA, Israel, March , 2017 /PRNewswire /OWC Pharmaceutical Research Corp.
February 24, 2017	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 22, 2017 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
February 24, 2017	EX-99	OWC Pharmaceutical Research Corp Receives IRB Approval To Initiate Safety Testing On Its Cannabinoid-Infused Cream For Treatment of Psoriasis Protocol Is The First Topical Medical Cannabis Treatment To Be Included In NIH Registry "Exhibit 99.1 OWC Pharmaceutical Research Corp Receives IRB Approval To Initiate Safety Testing On Its Cannabinoid-Infused Cream For Treatment of Psoriasis Protocol Is The First Topical Medical Cannabis Treatment To Be Included In NIH Registry PETACH TIKVA, Israel, February , 2017: OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "Company"), an Israeli-based developer of cannabinoid-
February 6, 2017	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 5, 2017 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
February 2, 2017	8-K	OWC Pharmaceutical Research (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 1, 2017 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
January 26, 2017	EX-99.17 (AS APPROP)	OWC Pharmaceutical Research Corp announces the nominations of Ms. Miriam Sani, MSc Eng., to its Advisory Board MSc Eng. Ms. Sani brings 26 years of unique bio-pharma regulatory expertise, specializing in production and commercialization of medical so OWC Pharmaceutical Research Corp announces the nominations of Ms. Miriam Sani, MSc Eng., to its Advisory Board MSc Eng. Ms. Sani brings 26 years of unique bio-pharma regulatory expertise, specializing in production and commercialization of medical solutions and compliance with regulatory protocols. PETACH TIKVA, Israel, Jan 27, 2017: OWC Pharmaceutical Research Corp. (OTCQB: OWCP), ("OWC" or the "
January 26, 2017	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 27, 2017 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
January 17, 2017	8-K	OWC Pharmaceutical Research (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): January 17, 2017 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
January 17, 2017	EX-99.2	PETACH-TIKVA, Israel, January 17, 2017 PRNewswire/ — EXHIBIT 99.2 PETACH-TIKVA, Israel, January 17, 2017 PRNewswire/ — OWC Pharmaceutical Research Corp. (OTCQB: OWCP), (“OWCP” or the “Company”), through its Israeli based fully owned subsidiary (One world Cannabis Ltd) , a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today released its annual letter to the Company’s shareholders. Dear Sha
January 12, 2017	EX-10.21	Research Agreement between One World Cannabis Ltd and Medical Research Infrastructure Development and Health Services Fund by Chaim Sheba Medical Center dated December 29, 2016 (incorporated by reference to Exhibit 10.21 to the Company’s Current Report on Form 8-K filed on January 12, 2017). EXHIBIT 10.21 RESEARCH AGREEMENT This Research Agreement (?Agreement?) is made and entered into this 29th day of December, 2016, by and between One World Cannabis Ltd., a company duly incorporated under the laws of the State of Israel, having its registered office at 7 Imber Street, Petach Tikva, 4951141, Israel, by its authorized representative, Mr. Ziv Turner, CEO (the ?Company?) and: Medical Re
January 12, 2017	8-K	OWC Pharmaceutical Research (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 29, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
December 28, 2016	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 23, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
December 28, 2016	EX-16	December 27, 2016 December 27, 2016 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have read the statements included under Item 4.01 of Form 8-K dated December 27, 2016, of OWC Pharmaceutical Research Corp., to be filed with the Securities and Exchange Commission and we agree with such statements insofar as they relate to our firm. We have no basis to agree or disagree with other sta
December 22, 2016	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 21, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
December 22, 2016	EX-10	Consulting Services Agreement Consulting Services Agreement This Corporate Advisory Consulting Agreement (this "Agreement"), is made as of December 16, 2016, between OWC Pharmaceutical Research Corp.
December 22, 2016	EX-10	Corporate Management Consulting Agreement Corporate Management Consulting Agreement This Corporate Management Consulting Agreement (this "Agreement"), is made as of November 21, 2016, between OWC Pharmaceutical Research Corp.
November 29, 2016	EX-99	WOODS LONERGAN& READ EXHIBIT 99.1 WOODS LONERGAN& READ PLLC ATTORNEYS AT LAWwoodslonergan.com Lawrence R. Lonergan, Esq. Partner Admitted to the NY, NJ and MA Bar Writer?s Email: [email protected] 280 Madison Avenue, Suite 300 New York, NY 10016 Tel: 212 684 2500 Fax: 212 684 2512 The Lonergan Law Firm, LLC 96 Park Street Montclair, NJ 07042 Tel: 973 641 4012 Reply to New York, NYJ By E-Mail and Federal Express Marc
November 29, 2016	8-K	OWC Pharmaceutical Research (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 28, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
November 28, 2016	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 27, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
November 28, 2016	EX-10	License Agreement between the Company and Emilia Cosmetics Ltd dated November 27, 2016 (incorporated by reference to Exhibit 10.19 to the Company’s Form 8-K filed on November 28, 2016). Exhibit 10.19 LICENSE AGREEMENT This License Agreement (this "Agreement"), entered into on November 27, 2016 (the "Effective Date"), is entered into by and between Emilia Cosmetics Ltd., a company organized under the laws of the State of Israel ("Emilia"), OWC Pharmaceutical Research Corp., a company organized under the laws of the State of Delaware of USA ("OWCP"), One World Cannabis Ltd., a comp
November 22, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 21, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
November 14, 2016	10-Q	OWC Pharmaceutical Research FORM 10-Q FOR THE PERIOD ENDED SEPTEMBER 30, 2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 98-0573566 (State of Incorporation) (I.R.S. Emplo
November 7, 2016	EX-17	Dr. Asaf Toker Exhibit 17.3 Dr. Asaf Toker October 31, 2016 Board of Directors OWC Pharmaceutical Research Corp. 22 Shacham Street, P.O.B. 8324 Petach Tikva, 4918103 Israel Re: Letter of Resignation Gentlemen: I hereby resign as Chief Science Officer of OWC Pharmaceutical Research Corp. (the "Registrant"), effective November 2, 2016. The reason for my resignation is to permit me to pursue other business interest
November 7, 2016	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 2, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
November 4, 2016	EX-10	Unit Subscription Agreement dated November 3, 2016 (incorporated by reference to Exhibit 10.17 to the Company’s Form 8-K filed on November 4, 2016). Exhibit 10.17 THIS SUBSCRIPTION AGREEMENT RELATES TO AN OFFERING OF UNITS (THE "UNIT OFFERING"), EACH UNIT COMPRISED OF ONE (1) SHARE OF COMMON STOCK (THE "SHARES") AND ONE (1) CLASS B COMMNON STOCK PURCHASE WARRANT (THE "CLASS B WARRANT"). THE UNIT OFFERING IS BEING IN AN OFFSHORE TRANSACTION TO PERSONS WHO ARE NOT U.S. PERSONS (AS DEFINED HEREIN) PURSUANT TO REGULATION S PROMULGATED BY THE UNITE
November 4, 2016	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 3, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
November 4, 2016	EX-10	Memorandum of Understanding between the Company and Michepro Holding Ltd. dated November 3, 2016 (incorporated by reference to Exhibit 10.18 to the Company’s Form 8-K filed on November 4, 2016). Exhibit 10.18 MEMORANDUM OF UNDERSTANDING THIS MEMORANDUM OF UNDERSTANDING ("JV/MOU") is entered into on the date set forth on the signature page hereof. BETWEEN: One World Cannabis Ltd. ("OWC"), a legal entity organized under the laws of the State of Israel, having a place of business at 22, Shacham Street, Petach Tikva, Israel, herein acting and represented by Ziv Turner, its Chief Operating Off
October 24, 2016	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 14, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
October 24, 2016	10-Q/A	OWC Pharmaceutical Research FORM 10-Q/A FOR THE PERIOD ENDED JUNE 30, 2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 98-0573566 (State or other Jurisdiction of Incorporation) (IRS Em
October 18, 2016	10-Q/A	OWC Pharmaceutical Research FORM 10-Q/A FOR THE PERIOD ENDED JUNE 30, 2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 98-0573566 (State or other Jurisdiction of Incorporation) (IRS Em
October 18, 2016	CORRESP	OWC Pharmaceutical Research ESP OWC PHARMACEUTICAL RESEARCH CORP OWC PHARMACEUTICAL RESEARCH CORP. 22 Shaham Street, P.O. Box 8324 Petach Tikva, 4918103 Israel October 18, 2016 United States Securities and Exchange Commission Washington, DC 20549 Attn: Kevin J. Kuhar, Accounting Branch Chief OWC Pharmaceutical Research Corp. Form 10-Q for the Quarterly Period Ended June 30, 2016 File August 29, 2016 File No. 0-54856 Ladies and G
October 17, 2016	RW	OWC Pharmaceutical Research REGISTRATION WITHDRAWAL REQUEST OWC Pharmaceutical Research Corp. 22 Shaham Street, P.O. Box 8324 Petach Tikva, 4918103 Israel Application for Withdrawal of Registration Statement October 17, 2016 U.S. Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Registration Statement on Form S-1 Filed on June 16, 2016 File No. 333-212058 Ladies and Gentlemen: Pursuant to Rule 477 under the Securitie
October 14, 2016	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) dyap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 14, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation
October 6, 2016	SC 13G/A	OWCP / OWC Pharmaceutical Research Corp. / VIS VIRES GROUP, INC. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1)* OWC PHARMACEUTICAL RESEARCH CORP. (Name of issuer) Common Stock, $0.00001 par value per share (Title of class of securities) 67109N108 (CUSIP number) October 3, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
September 29, 2016	8-K	OWC Pharmaceutical Research (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): September 22, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 333-209530 Delaware 98-0573566 (State of Incorporation
September 29, 2016	EX-10.9	Loan Agreement between the Company and Medmar LLC, dated September 28, 2016 (incorporated by reference to Exhibit 10.9 to the Company’s Form 8-K filed on September 30, 2016). EXHIBIT 10.9 LOAN AGREEMENT THIS LOAN AGREEMENT (this ?Agreement?) by and between Medmar LLC., a legal entity constituted under the laws of the State of Maryland, USA (?Medmar? or ?Lender?) and One World Cannabis Ltd., a company organized under the laws of the State of Israel (?OWC? or ?Borrower?) , duly executed and delivered on this 28th day of September, 2016, is, effective as of September 22,
August 29, 2016	10-Q	OWC Pharmaceutical Research FORM 10-Q FOR THE PERIOD ENDED JUNE 30, 2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _ FORM 10-Q _ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 98-0573566 (State or other Jurisdiction of Incorporation) (IRS
August 16, 2016	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K/A ___________________________________ ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 98-0573566 (State of Incorporation) (I.R.S. Employer Ide
August 16, 2016	CORRESP	OWC Pharmaceutical Research ESP OWC PHARMACEUTICAL RESEARCH CORP. 22 Shaham Street, P.O. Box 8324 Petach Tikva, 4918103 Israel August 16, 2016 United States Securities and Exchange Commission Washington, DC 20549 Attn: Kevin J. Kuhar, Accounting Branch Chief OWC Pharmaceutical Research Corp. Form 10-K for the Fiscal Year Ended December 31, 2015 Filed April 14, 2016 File No. 0-54856 Ladies and Gentlemen: This letter is in respons
August 16, 2016	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K/A ___________________________________ ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 98-0573566 (State of Incorporation) (I.R.S. Employer Ide
August 16, 2016	CORRESP	OWC Pharmaceutical Research ESP OWC PHARMACEUTICAL RESEARCH CORP. 22 Shaham Street, P.O. Box 8324 Petach Tikva, 4918103 Israel August 16, 2016 United States Securities and Exchange Commission Washington, DC 20549 Attn: Kevin J. Kuhar, Accounting Branch Chief OWC Pharmaceutical Research Corp. Form 10-K for the Fiscal Year Ended December 31, 2015 Filed April 14, 2016 File No. 0-54856 Ladies and Gentlemen: This letter is in respons
August 12, 2016	NT 10-Q	OWC Pharmaceutical Research LATE NOTIFICATION DYAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OWC Pharmaceutical Research Corp. (Full Name of Registrant) FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54856 (Check One): [ ]Form 10-K [ ] Form 20-F [ ]Form 11-K [ ] Form 10Q [ ] Form N-SAR [ ] For Period Ended: [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report o
June 23, 2016	SC 13G	OWCP / OWC Pharmaceutical Research Corp. / VIS VIRES GROUP, INC. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. )* OWC PHARMACEUTICAL RESEARCH CORP. (Name of issuer) Common Stock, $0.00001 par value per share (Title of class of securities) 67109N108 (CUSIP number) June 11, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
June 16, 2016	EX-10.16	Convertible Promissory Note issuable to Vis Vires Group, Inc. dated February 2, 2016 (incorporated by reference to Exhibit 10.16 to the Company’s S-1 filed on June 16, 2016). EX-10.16 11 ex10-16.htm
June 16, 2016	S-1	As filed with the Securities and Exchange Commission on June 16, 2016 As filed with the Securities and Exchange Commission on June 16, 2016 Registration No.
June 16, 2016	EX-10.15	Securities Purchase Agreement between the Company and Vis Vires Group, Inc. dated February 2, 2016, (incorporated by reference to Exhibit 10.15 to the Company’s S-1 filed on June 16, 2016). EX-10.15 10 ex10-15.htm
June 16, 2016	EX-10.14	Services Agreement between the Company and Shmuel De-Saban dated January 31, 2016, (incorporated by reference to Exhibit 10.14 to the Company’s S-1 filed on June 16, 2016). EX-10.14 9 ex10-14.htm
June 16, 2016	EX-10.7	EX-10.7 EX-10.7 5 ex10-7.htm
June 16, 2016	EX-10.5	EX-10.5 EX-10.5 3 ex10-5.htm
June 16, 2016	EX-10.13	Stock Option Agreement between the Company and Dr. Asaf Toker, former CSO, dated January 18, 2018, filed with the Company’s S-1 on June 16, 2016. EX-10.13 8 ex10-13.htm
June 16, 2016	EX-10.12	Termination Agreement and Mutual General Release between the Company and GUMI Tel Aviv Ltd dated February 3, 2016 (incorporated by reference to Exhibit 10.12 to the Company’s S-1 filed on June 16, 2016). EX-10.12 7 ex10-12.htm
June 16, 2016	EX-10.6	EX-10.6
June 16, 2016	EX-10.3	EX-10.3 EX-10.3 2 ex10-3.htm
June 16, 2016	EX-10.8	EX-10.8
May 24, 2016	EX-10	AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT Exhibit 10.2 AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT AMENDMENT NO. 1 TO REGISTRATION RIGHTS AGREEMENT dated as of May 17, 2016 (the ?Amendment?), is made by and between OWC Pharmaceutical Research Corp., a Delaware corporation (the ?Company?) and Kodiak Capital Group, LLC, a Delaware limited liability company (the ?Investor?). RECITALS A. Company and Investor entered into that certain Reg
May 24, 2016	EX-10	AMENDMENT NO. 1 TO EQUITY PURCHASE AGREEMENT Exhibit 10.1 AMENDMENT NO. 1 TO EQUITY PURCHASE AGREEMENT AMENDMENT NO. 1 TO EQUITY PURCHASE AGREEMENT dated as of May 17, 2016 (the ?Amendment?), is made by and between OWC Pharmaceutical Research Corp., a Delaware corporation (the ?Company?) and Kodiak Capital Group, LLC, a Delaware limited liability company (the ?Investor?). RECITALS A. Company and Investor entered into that certain Equity Purc
May 24, 2016	8-K	OWC Pharmaceutical Research (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): May 17, 2016 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 333-209530 Delaware 98-0573566 (State of Incorporation) (I.R
May 16, 2016	10-Q	OWC Pharmaceutical Research FORM 10-Q FOR THE PERIOD ENDED MARCH 31, 2016 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 98-0573566 (State or other Jurisdiction of Incorporation) (IRS Emp
May 5, 2016	RW	OWC Pharmaceutical Research WITHDRAWAL OF REGISTRATION STATEMENT ON FORM S-1 OWC Pharmaceutical Research Corp. 22 Shaham Street, P.O. Box 8324 Petach Tikva, 4918103 Israel Application for Withdrawal of Registration Statement May 5, 2016 U.S. Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Registration Statement on Form S-1 Filed on February 12, 2016, as amended on February 16, 2016 File No. 333-209530 Ladies and Gentlemen: Pursuant
April 14, 2016	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K ___________________________________ ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal ye UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 98-0573566 (State of Incorporation) (I.R.S. Employer Ident
March 30, 2016	NT 10-K	OWC Pharmaceutical Research LATE NOTIFICATION DYAP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OWC Pharmaceutical Research Corp. (Full Name of Registrant) FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54856 (Check One): [X]Form 10-K [ ] Form 20-F [ ]Form 11-K [ ] Form 10Q [ ] Form N-SAR [ ] For Period Ended: [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report o
February 16, 2016	S-1/A	As filed with the Securities and Exchange Commission on February 16 , 2016 S-1/A 1 forms-1a.htm As filed with the Securities and Exchange Commission on February 16 , 2016 Registration No. 333- 209530 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 /A AMENDMENT NO . 1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OWC PHARMACEUTICAL RESEARCH CORP. (Exact name of registrant as specified in its charter) Delaware 3841 98-0573566 (Sta
February 12, 2016	S-1	OWC Pharmaceutical Research As filed with the Securities and Exchange Commission on February 12, 2016 Registration No.
December 23, 2015	8-K	OWC Pharmaceutical Research (Current Report/Significant Event) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): December 17, 2015 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I
December 23, 2015	EX-10.9	FORM OF EQUITY PURCHASE AGREEMENT EXHIBIT 10.9 FORM OF EQUITY PURCHASE AGREEMENT THIS EQUITY PURCHASE AGREEMENT entered into as of the day of , 2015 (this “AGREEMENT”), by and between KODIAK CAPITAL GROUP, LLC, a Delaware limited liability company (“INVESTOR”), and OWC PHARMACEUTICAL RESEARCH CORP., a Delaware corporation (the “COMPANY”). WHEREAS, the parties desire that, upon the terms and subject to the conditions contained here
December 23, 2015	EX-10.11	OWC PHARMACEUTICAL RESEARCH CORP. FORM OF CONVERTIBLE PROMISSORY NOTE DUE JUNE 16, 2016 EXHIBIT 10.11 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR
December 23, 2015	EX-10.10	FORM OF REGISTRATION RIGHTS AGREEMENT EXHIBIT 10.10 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (“Agreement”), dated , is made by and between OWC PHARMACEUTICAL RESEARCH CORP., Delaware corporation (“Company”), and KODIAK CAPITAL GROUP, LLC a Delaware limited liability company (the “Investor”). RECITALS WHEREAS, upon the terms and subject to the conditions of the Equity Purchase Agreement (“Purchase Agreem
November 17, 2015	RW	OWC Pharmaceutical Research WITHDRAWAL OF REGISTRATION STATEMENT ON FORM S-1 OWC Pharmaceutical Research Corp. 22 Shaham Street, P.O. Box 8324 Petach Tikva, 4918103 Israel Application for Withdrawal of Registration Statement November 17, 2015 U.S. Securities and Exchange Commission Division of Corporation Finance Washington, D.C. 20549 Registration Statement on Form S-1 Filed April 23, 2015, as amended June 9, 2015 and August 13, 2015 File No. 333-203581 Ladies and Gentlem
November 13, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 10-Q ___________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended Septemb UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 98-0573566 (State of Incorporation) (I.R.S. Emplo
October 29, 2015	EX-10	MEMORANDUM OF UNDERSTANDING EXHIBIT 10.10 MEMORANDUM OF UNDERSTANDING THIS MEMORANDUM OF UNDERSTANDING ("MOU") is entered into on the date set forth on the signature page hereof. BETWEEN: One World Cannabis Ltd, a legal entity organized under the laws of the State of Israel, having a place of business at 22, Shacham Street, Petach Tikva, Israel, herein acting and represented by Ziv Turner, its Chief Executive Officer, duly a
October 29, 2015	8-K	OWC Pharmaceutical Research CURRENT REPORT (Current Report/Significant Event) dyap UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 29, 2015 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation
October 29, 2015	EX-10	MEMORANDUM OF UNDERSTANDING EXHIBIT 10.9 MEMORANDUM OF UNDERSTANDING THIS MEMORANDUM OF UNDERSTANDING ("MOU") is entered into on the date set forth on the signature page hereof. BETWEEN: One World Cannabis Ltd, a legal entity organized under the laws of the State of Israel, having a place of business at 22, Shacham Street, Petach Tikva, Israel, herein acting and represented by Ziv Turner, its Chief Executive Officer, duly au
October 14, 2015	EX-17	Dr. Alan Shackelford Exhibit 17.3 Dr. Alan Shackelford September 12, 2015 Board of Directors OWC Pharmaceutical Research Corp. Petach Tikva, Israel Re: Letter of Resignation Gentlemen: I hereby resign as Chief Science Officer of One World Cannabis Ltd, a wholly-owned subsidiary of OWC Pharmaceutical Research Corp. (the "Company"), effective immediately. The reason for my resignation is to permit me to pursue other bus
October 14, 2015	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): October 14, 2015 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
August 17, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 10-Q ___________________ ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 98-0573566 (State or other Jurisdiction of Incorporation) (IRS Empl
August 14, 2015	NT 10-Q	OWC Pharmaceutical Research LATE NOTIFICATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OWC Pharmaceutical Research Corp. (Full Name of Registrant) FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54856 (Check One): [ ]Form 10-K [ ] Form 20-F [ ]Form 11-K [ ] Form 10Q [X] Form N-SAR [ ] For Period Ended: [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on For
August 13, 2015	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment #2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment #2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 3841 98-0573566 (State or other Jurisdiction of Incorporation) (Primary Standard Industrial Classification Code) (IRS Employer Identification No.) 22 Shacham Steet,
August 13, 2015	EX-10	Service Agreement between the Company and Sheba Academic Medical Center, dated October 22, 2014, (incorporated by reference to Exhibit 10.8 to the Company’s S-1/A filed on August 13, 2015). ADDENDUM As of July 27, 2015 to SERVICE AGREEMENT As of October 22, 2014 Between Medical Research Infrastructure Development and Health Services Fund by the Chaim Sheba Medical Center (hereinafter: "the Fund") And One World Cannabis Ltd.
June 9, 2015	S-1/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment #1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 Amendment #1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 3841 98-0573566 (State or other Jurisdiction of Incorporation) (Primary Standard Industrial Classification Code) (IRS Employer Identification No.) 22 Shaham Steet, P
June 9, 2015	EX-10	Service Agreement between the Company and Sheba Academic Medical Center, dated October 22, 2014 (incorporated by reference to Exhibit 10.7 to the Company’s S-1/A filed on June 9, 2015). Service Agreement This Agreement (“Agreement”) is made and entered in Tel Aviv this 22 day of October, 2014 by and between Medical Research Infrastructure Development and Health Services Fund by the Chaim Sheba Medical Center, a nonprofit organization incorporated under the Laws of the State of Israel, represented by its authorized representative Sheba Medical Center (“the Fund”) A private company duly incorporated under the laws of the State of Israel having its registered office at Jaffa Shaeri Niknur 14, represented by its authorized representative, One World Cannabis .
June 9, 2015	EX-21	Subsidiaries of the Registrant One World Cannabis Ltd. ("OWC") incorporated under the laws of the State of Israel. Subsidiaries of the Registrant One World Cannabis Ltd. ("OWC") incorporated under the laws of the State of Israel.
May 15, 2015	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ FORM 10-Q ___________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 98-0573566 (State or other Jurisdiction of Incorporation) (IRS Emp
April 23, 2015	EX-10	Services Agreement between the Company and Mr. Bignitz, dated October 2, 2014 (incorporated by reference to Exhibit 10.5 to the Company’s Form S-1 filed on April 23, 2015). Exhibit 10.5 SERVICES AGREEMENT THIS SERVICES AGREEMENT (the "Services Agreement") is dated as of this 1st day of November, 2014, between Dynamic Applications Corp., a Delaware corporation (the "Company") and Mordechai Bignitz, a resident of the State of Israel (the "Executive"). The Company and the Executive are sometimes referred to collectively, as the "Parties" and individually, as a "Party."
April 23, 2015	EX-10	Services Agreement between the Company and Mr. De-Saban, dated October 2, 2014 (incorporated by reference to Exhibit 10.6 to the Company’s Form S-1 as filed on April 23, 2015). Exhibit 10.6 SERVICES AGREEMENT THIS SERVICES AGREEMENT (the "Agreement") is dated as of this 2nd day of October, 2014, between Dynamic Applications Corp., a Delaware corporation (the "Company") and Shmuel De-Saban, a resident of Israel (the "Advisor"). The Company and the Advisor are sometimes referred to collectively, as the "Parties" and individually, as a "Party." WHEREAS, the Company, though
April 23, 2015	S-1	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant in its Charter) Delaware 3841 98-0573566 (State or other Jurisdiction of Incorporation) (Primary Standard Industrial Classification Code) (IRS Employer Identification No.) 22 Shaham Steet, P.O. Box 8324,
April 1, 2015	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K ___________________________________ ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal ye UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2014 Commission file number 0-54856 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name Of Registrant As Specified In Its Charter) Delaware 98-0573566 (State of Incorporation) (I.R.S. Employer Ident
March 31, 2015	NT 10-K	OWC Pharmaceutical Research LATE NOTIFICATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OWC Pharmaceutical Research Corp. (Full Name of Registrant) FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 000-54856 (Check One): [X]Form 10-K [ ] Form 20-F [ ]Form 11-K [ ] Form 10Q [ ] Form N-SAR [ ] For Period Ended: [ ] Transition Report on Form 10-K [ ] Transition Report on Form 20-F [ ] Transition Report on For
March 4, 2015	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): March 4, 2015 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S
February 10, 2015	EX-99	EX-99
February 10, 2015	EX-99	EX-99
February 10, 2015	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): February 9, 2015 OWC PHARMACEUTICAL RESEARCH CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.
December 9, 2014	DEF 14C	OWCP / OWC Pharmaceutical Research Corp. DEF 14C - - DEFINITIVE INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: ¨ Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) x Definitive Information Statement Dynamic Applications Corp. (Name of
November 28, 2014	PRE 14C	OWCP / OWC Pharmaceutical Research Corp. PRE 14C - - PRELIMINARY INFORMATION STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14C INFORMATION Information Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Check the appropriate box: x Preliminary Information Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14c-5(d)(2)) ¨ Definitive Information Statement Dynamic Applications Corp. (Name of
November 17, 2014	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (date of earliest event reported): November 7, 2014 DYNAMIC APPLICATIONS CORP. (Exact Name of Registrant as Specified in its Charter) Commission File No.: 0-54856 Delaware 98-0573566 (State of Incorporation) (I.R.S. Em

OWCP / OWC Pharmaceutical Research Corp. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)